MD PhD | Nephrologist with interest in kidney autoimmunity at the @MedUniGraz | ERA YNP Board Member | views my own 🇪🇺
Joined December 2018
- Tweets 381
- Following 260
- Followers 408
- Likes 1,703
31 Photos and videos
Pinned Tweet
20 Dec 2024
Just published in @Kidney_Int - The impact of PLEX and GC on early kidney function changes in AAV. (kidney-international.org/art…) This analysis provides another important piece of the “PLEX puzzle”.
Many thanks to my co-authors, the PIs and especially to @AKronbichler and David Jayne.
4
5
31
1,614
Balazs Odler retweeted
Mar 18
👉🏻 Check out this month snapshot summary about CAKUT disease in adult patients
doi.org/10.1093/ndt/gfaf172
✍️Charlotte Hammett is the YNP author
Post prepared by @jt_nephrology
@NDTsocial
@ERAkidney
15
14
1,192
Balazs Odler retweeted
Mar 5
Apply to be a board member of the YNP! 👇🏻
💥 2026 ERA Open Calls: join the official ERA Bodies!
📅Apply by March 26, 2026 for:
🤝Working Groups: CKD-MBD, Diabesity, ERAKI, ERN, EuDial, G&K, IWG
📚Committees: ETHICS, Kidney Relief in Disasters, Strong Kidneys, Sustainable Nephrology, Young Nephrologists’ Platform, Women of ERA
🎙️Podcast Team
Apply now 👉 bit.ly/4hl2N1n
6
5
1,277
Balazs Odler retweeted
Feb 19
🪨 Kidney stones: Time to nephrologists to reclaim the field?
👀Check out our latest post with 10 tips on work-up and management of CKD
patients with nephrolithiasis.
Gerlineke Hawkins-van der Cingel is the YNP author
🧵by @jt_nephrology
@CKJsocial @ERAkidney
1
17
40
2,726
Balazs Odler retweeted
23 Dec 2025
I am glad to work together with leading experts in the field of rare kidney diseases! Together these diseases are common! Thank you @GlomCon
🚨 We are pleased to announce the upcoming launch of GlomCon’s Rare Kidney Disease Journal, a new peer-reviewed journal developed in partnership with @SpringerNature. This journal will serve as a global platform dedicated to advancing research, clinical practice, and innovation in rare and complex kidney diseases.
12
11
52
3,509
Balazs Odler retweeted
15 Dec 2025
🙌🏻 Check out this month snapshot summary about pharmacologial differences between man and woman with CKD
doi.org/10.1093/ndt/gfaf125
@SoleneLaville is the YNP author
Post prepared by @jt_nephrology
@ERAkidney @NDTsocial
12
16
1,445
Balazs Odler retweeted
24 Nov 2025
Apply now! Such a great opportunity! 👇🏻
24 Nov 2025
🚨 YNP Mentorship Programme: The applications for Mentees are open!
🌟 Are you a young professional or a medical student, trainee or fellow?
🔍 Discover the inspiring perspectives of mentees and mentors who have experienced it before you
🗓 Deadline: January 30, 2026
Apply now 👉 bit.ly/48dubvT
5
5
498
Balazs Odler retweeted
17 Oct 2025
1/ 🧬 CRISPR and gene editing for kidney diseases: Where do we stand in 2025?
A review on how CRISPR and other gene editing tools are redefining what’s possible in nephrology — from fixing mutations to regenerating kidney tissue.
@Violadmb is the YNP author
🧵 by @jt_nephrology
@CKJsocial @ERAkidney
1
10
13
1,275
31 May 2025
ANCA-negative pauci-immune glomerulonephritis must be one of the most challenging fields in vasculitis. In this commentary in @KIReports, we discuss some open questions on this topic.
kireports.org/article/S2468-…
16
33
1,681
Balazs Odler retweeted
We’re calling on researchers, clinicians, and educators—share your work with the global vasculitis community!
Submit your abstract by 19 September 2025—don’t miss your chance to be part of this exciting event!
vasculitis-melbourne2026.com…
#VasculitisMelbourne2026
18
23
3,568
Balazs Odler retweeted
7 May 2025
📢 Join us at the YNP & EFIM joint e-seminar: *Cardiorenal Syndrome – Perspectives from Nephrology and Internal Medicine*
📅 Wednesday, May 14, 2025, 5:00 PM (CEST)
Register now 👉 bit.ly/4jXCuQA
8
24
2,584
Balazs Odler retweeted
24 Mar 2025
1/ New thread on recently published @CKJsocial paper by @luisloureiro4 using target trial emulation to assess impact of arteriovenous fistula 🩸 formation on kidney function decline 📉
Link 👉 doi.org/10.1093/ckj/sfae345
🧵by @richard_shemilt
1
13
13
1,236
12 Mar 2025
Recently, post-hoc analyses of the PEXIVAS trial have provided new insights into the use of PLEX in #AAV. In this viewpoint, we highlight clinical scenarios where its use may be benefical. Don’t miss „Viewpoint 1“ by Mike Walsh.
academic.oup.com/rheumatolog…
1
8
22
9,394
13 Feb 2025
Check out our newest paper on a practical approach to common nephrology consultations. 👇🏻
Great job @KollandMichael, @saberger_ , @alehkir ! 👌🏻
academic.oup.com/ckj/advance…
1
8
20
821
Balazs Odler retweeted
15 Jan 2025
The effects of #plasmaexchange and #glucocorticoids on early kidney function among patients with #ANCA-associated #vasculitis in the PEXIVAS trial
doi.org/10.1016/j.kint.2024.…
#OpenAccess #glomerulonephritis #ESKD
36
81
6,677
Balazs Odler retweeted
8 Jan 2025
✅ Let's see who will bring forward the best arguments 😏😇 #Lupus nephritis - standard of care (for all, will already be something)
7 Jan 2025
Debate 3 at #CORA2025: LN Treatment—Early Combination vs. Standard?
🔸 Ioannis Parodis (Sweden) argues for Early Combination
🔸 Laurent Arnaud (France) advocates for Standard Treatment
Review the topics: bit.ly/4fGmsZ0
#Lupus #SLE #Rheumatology #Autoimmunity #Rheum
3
12
51
3,179
Balazs Odler retweeted
30 Dec 2024
Lupus nephritis: redefining the treatment goals
doi.org/10.1016/j.kint.2024.…
#KIEditorial #OpenAccess #lupusnephritis
@MayoClinicNeph @MayoClinicPath
1
82
193
11,391
Balazs Odler retweeted
Website's up!
vasculitis-melbourne2026.com…
All things #vasculitis in Melbourne Feb 2026. Key dates, things to do and promotional tools, with more to follow
Come for exceptional research, learning and interactions over 5 days
And....a great trip to Australia and New Zealand!
1
10
30
3,225
Balazs Odler retweeted
20 Nov 2024
👀 Check our new snapshot summary on fluid removal targets during intermittent renal replacement therapy for AKI!
doi.org/10.1093/ckj/sfae257
@WBeaubien is the YNP author.
Prepared by @smirioglu.
@ERAkidney @CKJsocial
1
17
15
4,604